Impax Laboratories Inc (IPXL.OQ)

IPXL.OQ on NASDAQ Stock Exchange Global Select Market

20.98USD
2:58pm EDT
Price Change (% chg)

$0.15 (+0.72%)
Prev Close
$20.83
Open
$20.80
Day's High
$21.02
Day's Low
$20.74
Volume
48,476
Avg. Vol
286,146
52-wk High
$27.25
52-wk Low
$14.41

IPXL.OQ

Chart for IPXL.OQ

About

Impax Laboratories Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products. The Company operates in two segments: Global Pharmaceuticals... (more)

Overall

Beta: 0.32
Market Cap (Mil.): $1,426.38
Shares Outstanding (Mil.): 68.48
Dividend: --
Yield (%): --

Financials

  IPXL.OQ Industry Sector
P/E (TTM): 9.55 38.06 37.87
EPS (TTM): 2.18 -- --
ROI: 19.96 19.42 18.70
ROE: 20.91 20.10 19.53
Search Stocks

Impax, GSK end Parkinson's disease partnership

- Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.

29 Apr 2013

Impax, GSK end Parkinson's disease partnership

April 29 - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.

29 Apr 2013

Impax shares drop as FDA flags new concerns on manufacturing plant

- Impax Laboratories Inc said U.S. health regulators raised fresh concerns related to manufacturing practices at the drugmaker's Hayward, California facility, sending its shares down more than 20 percent after the bell.

04 Mar 2013

BRIEF-Shire, Impax settle litigation related to Adderall XR

LONDON, Feb 8 - Shire PLC : * Unit has settled all pending litigation with Impax Laboratories * Litigation was over shire's supply of an authorized generic version of

08 Feb 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$472.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks